Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565330 · ClinicalTrials.gov registry record · Phase 1
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
A Phase 1 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT01565330: Completed Phase 1 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
NCT01565330 is a Phase 1 study of Alzheimer Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 20 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01565330, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
Primary Outcome
Visual evaluation of image quality by nuclear medicine specialist blinded to dose and clinical information; reported on a 5-point scale (5=excellent and 1=poor).
Conditions Studied
Interventions
- DRUG florbetapir F 18
Study Locations (3)
Florida
- Research Site - West Palm Beach
Maryland
- Research Site - North East
New Jersey
- Research Site - Clementon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
What the finished NCT01565330 record still lists
NCT01565330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT01565330 reports a single indexed study location in Florida, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01565330 about?
NCT01565330 is a clinical study titled "A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers". This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
What is the current status of trial NCT01565330?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-03. Estimated completion is 2008-08.
What conditions does trial NCT01565330 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT01565330?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT01565330?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01565330 being conducted?
This trial has 3 study locations across Florida, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01565330's enrollment target sits among peer trials
20 264th of 306 higher than 32 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia